California is currently home to 5597 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1 Trial of ST-001 NanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
NCT04234048
Recruiting
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: City of Hope Medical Foundation, Duarte, California
Conditions: T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Register for Updates
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802
Recruiting
This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/21/2025
Locations: Benchmark Research, Sacramento, California
Conditions: Encephalitis
Register for Updates
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
NCT06712251
Recruiting
The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/21/2025
Locations: Apex Research, Riverside, California
Conditions: Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Register for Updates
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
NCT06614192
Recruiting
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). ABBV-400 is an investigational drug being developed for the treatment of CRC. Participants are put int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: City of Hope National Medical Center /ID# 267875, Duarte, California
Conditions: Metastatic Colorectal Cancer
Register for Updates
MDMA-assisted Massed Prolonged Exposure for PTSD
NCT06117306
Recruiting
The overall objective of this study is to pilot the VASDHS-adapted Emory MDMA-PE Protocol (aE-MDMA-PE) and assess the effect on clinician-rated PTSD symptoms in veterans who receive full-dose MDMA and veterans who receive low-dose MDMA.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/21/2025
Locations: VA San Diego Healthcare System, San Diego, CA, San Diego, California
Conditions: Post-Traumatic Stress Disorder
Register for Updates
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
NCT06015308
Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Orange County Clinical Trials- Site Number : 8401271, Anaheim, California
Conditions: Dermatitis Atopic
Register for Updates
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
NCT05929703
Recruiting
The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following: 1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity. 2. To compare the effectiveness of FAM-HELP and HELP in improving patien... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
03/21/2025
Locations: Saddleback Medical Center, Orange, California
Conditions: Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease, Aging, Family Support, Family Members, Caregiver Burden, Implementation Science, Patient Satisfaction
Register for Updates
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT05663502
Recruiting
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: UC San Diego Moores Cancer Center, La Jolla, California
Conditions: Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
Register for Updates
PV Loop & Coarctation Study
NCT05362721
Recruiting
Coarctation of the aorta accounts for 4-7% of all congenital heart disease. While stent therapy, when feasible, is the standard of care for coarctation, it may not completely improve the work (and afterload) of the heart due to its effects on the elasticity of the aorta. This study will provide the information needed to understand the effects of current management on the cardiac mechanics and work.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/21/2025
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Coarctation of Aorta
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: University of California San Diego Moores Cancer Center, La Jolla, California
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833
Recruiting
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Pha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263
Recruiting
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Gender:
ALL
Ages:
Between 0 hours and 24 hours
Trial Updated:
03/21/2025
Locations: Children's Hospital of Orange County, California City, California
Conditions: Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Register for Updates